Dr. Gergel will have oversight for the company's clinical strategy and activities, including direct supervision of clinical research, clinical operations, medical affairs, regulatory affairs, and drug safety and surveillance.I am exceptionally pleased that Ivan is joining the Nektar executive team, said Howard W. Robin, President and CEO of Nektar Therapeutics.